Key result
Tailored COVID-19 management in heart failure mitigates arrhythmia and congestion risks during antiviral and corticosteroid therapy.
Why the study?
The relationship between heart failure and COVID-19 remains questioned and poorly elucidated, requiring specific management strategies to avoid complications.
This narrative review highlights the complex interplay between acute COVID-19 and heart failure, emphasizing the need for careful ECG monitoring, diuretic titration during corticosteroid therapy, and telemonitoring to prevent arrhythmic complications and acute decompensation.
Answers are grounded in this paper and cite their sources.
Supports monitoring during antiviral/corticosteroid therapy in COVID-19 heart failure; leaves open randomized validation of risk reduction.
The relationship existing between heart failure (HF) and COVID-19 remains questioned and poorly elucidated. Many reports suggest that HF events are reduced during pandemics, although other studies have demonstrated higher mortality and sudden death in patients affected by HF. Several vascular, thrombotic, and respiratory features may deteriorate stable HF patients; therefore, the infection may directly cause direct myocardial damage, leading to cardiac function deterioration. Another concern is related to the possibility that antiviral, anti-inflammatory, and corticosteroid agents commonly employed during acute COVID-19 infection may have potentially deleterious effects on the cardiovascular (CV) system. For these reasons, HF patients deserve specific management with a tailored approach in order to avoid arrhythmic complications and fluid retention events. In this review, we describe the complex interplay between COVID-19 and HF, the evolving trend of infection with related CV events, and the specific management strategy to adopt in this setting.
No takes yet. Share an insight, caveat, or question.
Palazzuoli et al. (2023) conducted a review in Heart failure and acute COVID-19 infection. Tailored inpatient and outpatient COVID-19 and heart failure management (antivirals, anti-inflammatories, corticosteroids, SGLT2 inhibitors, and telemonitoring) was evaluated. Tailored management of acute COVID-19 in heart failure patients, including ECG and fluid monitoring during antiviral and corticosteroid therapy, mitigates arrhythmic and congestion risks.
Synapse has enriched 10 related papers. Consider them for comparative context: